US · Healthcare · Biotechnology
EPS came in at -0.64 against a street estimate of -0.58 — a miss of 10.3%.
Analysts rate Tyra Biosciences Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $51.97.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 20.51% |
| FMR Inc | 13.03% |
| Nextech Invest, Ltd. | 6.82% |
| HHG PLC | 6.54% |
| Alta Partners Management Company, L.P. | 6.43% |
| Farallon Capital Management, L.L.C. | 6.02% |
| TCG Crossover Management, LLC | 5.46% |
| COMMODORE CAPITAL LP | 4.16% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-02 |
| Quarterly report · Q1 2026 | 2026-05-13 |
| Results announced · Q2 2026 | 2026-05-13 |
| Proxy statement · Q2 2026 | 2026-04-17 |
| Board / officer change · Q2 2026 | 2026-04-17 |
| Board / officer change · Q2 2026 | 2026-04-02 |
| Annual report FY2025 | 2026-03-02 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tyra Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.